VIVK DD>> Vivakor, Inc. is a biotechnology holding company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life.
VIVAKOR INC, has developed cutting edge technology which helps to preserve Stem Cells present in the body so that they can be used later on in life!
Vivakor is in a unique position in the market where they are large enough to develop ground breaking and innovative technologies in the stem cell field, but, also small enough that they are a great buyout target in the medical sector! Vivakor has been trading in the .09-.20 area for a while, and with the announcement of new product lines, and or joint ventures they are poised to explode to the forefront of research companies in their field. The biotechnology industry is posting some great numbers as a whole over the last year!. The 3 month average is +13.42%, the 6 month average is +14.76% and the 1 year is +35.25%! Vivakor is in a fast growing area of focus in the USA!
VIVAKOR has announced 4 different products:
#1 Vivathermic Vials, VivaThermic CryoVial Technology. We are actively developing the technologies required for the cryopreservation of diverse biological samples with improved recovery of viable cells post-cryopreservation. Emphasis has been placed on strategies to eliminate the variations and time delays experienced in the current biopsy and tissue preservation procedure by integrating a cryogenic freezing capacity into the biopsy device.
Critical advancements in biological sample preservation are evolving. We have developed specialized cryovials that accommodate an improved method of cryopreservation of cells, blood, and other bio-materials. When cryopreserving biological materials, the rate of cooling is the main factor affecting the cell viability. Material choice and design features of cryovials are critical parameters affecting the cooling rate. Existing cryovials do not allow for rapid freezing. They are usually manufactured from conventional polypropylene which is a poor thermally conductive material. In addition, they offer no special design features to enhance heat transfer.
Our cryovials benefit from better designs, a unique cap feature and improved use of materials resulting in better performance during the freezing and thawing process. The target markets for our cryovials include clinical laboratories, hospitals, fertility clinics, veterinarians, agribusiness, animal breeding and research laboratories.
#2 Vivaslices, SLICES?.? Our acquisition of HealthAmerica?s SLICES? technology will provide a technology platform for optimization and adaptation by our scientists.? This patented technology has received FDA 510(k) clearance? and it is intended that this technology will enhance the resolution of images resulting from MRI.? The underlying algorithm may be useful in the determination of blood flow velocity measures in imaged tissues.? Such information would be valuable in accessing areas of blood flow constriction from plaques or other hematologic deposits.? This information could help physicians better diagnose, predict and assess stroke and related diseases involving blood flow obstruction.
#3 Vivasight,VivaSight (Digital PhotoRefractor or DPR). We have developed a device that we expect will modernize screening of pre-verbal and pre-literate children for ocular disorders.? This type of screening is increasingly required by state governments prior to enrollment in the public school system.? Our scientists are collaborating with physicians and clinicians at University of Iowa Hospitals & Clinics Department of Ophthalmology & Visual Sciences to develop a clinic-ready device.
Data from the National Eye Institute (NEI) states that 2.3 million children have undiagnosed eye disorders that can lead to blindness if left untreated.? Amblyopia, commonly known as ?lazy eye?, is the leading cause of monocular vision loss in the 20 to 70+ age range.? It causes more vision loss than diabetic retinopathy, glaucoma, macular degeneration, and cataracts. Amblyopia occurs when the optical powers of the two eyes are different and the brain favors the visual signal from one eye, functionally ignoring the vision in the amblyopic eye. According to the NEI, an estimated 300,000 to 750,000 children between the ages of three to five suffer from amblyopia.? Visual acuity develops principally during the pre-school years, from birth to about five years old, as a child?s visual experience molds its genetic blueprint into its adult visual sensory system. If treatment is not initiated during the visual maturation period, the prognosis for normal visual development is poor.? Amblyopia can be reversed and cured if it is detected and treated during the critical visual development period. Unfortunately, less than 21% of preschool children receive some form of vision screening each year. Even those who are screened are often improperly screened by a general health practitioner, pediatrician or screening volunteer due to inadequate experience and lack of equipment or techniques for an assiduous exam. Some children receive proper eye exams once they start school; unfortunately by then it may be too late to effectively treat amblyopia.
Our DPR has been designed with ongoing end-user input to produce a device that will readily penetrate and gain wide acceptance in the vision screening market.? Most importantly our DPR offers all screening programs a low cost device with a high sensitivity and specificity. This device will streamline the screening process by the following: 1) Eliminate recurring cost of Polaroid film, 2) Instantaneously image a subject across two meridians of strabismus and refractive error,? 3) Detect improper subject fixation, 4) Digitize and automate the interpretation process, 5) Quantify the image interpretation and adjust the referral criteria based upon screening demographics to achieve predetermined levels of sensitivity and specificity, and 6) Give an instant refer/do not refer response to the screener.? This device is currently in clinical testing and is in Phase II of the development process.? On May 5, 2009, the National Institute of Health through the National Eye Institute awarded us a Phase I Small Business Innovation Research Award grant in the amount of $112,912 to conduct research related to the development of the our DPR and the detection of amblyogenic risk factors.
#4 Vivablend, VivaBlend (USPTO Provisional Patent#61093311). Our proprietary balanced blend of more than 18 different sources of? phytochemical extracts from antioxidant rich bioactive fruits and vegetables tested by the USDA that can be added to many consumer foods, drinks and nutraceuticals as a convenient daily source of important antioxidants and other critical bioactive phytochemicals.
Market Data 
Markets 
AI
